CY1123007T1 - Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b - Google Patents
Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2bInfo
- Publication number
- CY1123007T1 CY1123007T1 CY20201100280T CY201100280T CY1123007T1 CY 1123007 T1 CY1123007 T1 CY 1123007T1 CY 20201100280 T CY20201100280 T CY 20201100280T CY 201100280 T CY201100280 T CY 201100280T CY 1123007 T1 CY1123007 T1 CY 1123007T1
- Authority
- CY
- Cyprus
- Prior art keywords
- azaindoles
- substituted
- receptor regulators
- glun2b receptor
- nr2b receptor
- Prior art date
Links
- 108010054200 NR2B NMDA receptor Proteins 0.000 title 1
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 3
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical class C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562190416P | 2015-07-09 | 2015-07-09 | |
| PCT/US2016/041339 WO2017007938A1 (en) | 2015-07-09 | 2016-07-07 | Substituted 4-azaindoles and their use as glun2b receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123007T1 true CY1123007T1 (el) | 2021-10-29 |
Family
ID=56497884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100280T CY1123007T1 (el) | 2015-07-09 | 2020-03-24 | Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9963447B2 (https=) |
| EP (1) | EP3319963B1 (https=) |
| JP (2) | JP6964576B2 (https=) |
| KR (1) | KR20180026760A (https=) |
| CN (1) | CN108026094B (https=) |
| AU (1) | AU2016291158B2 (https=) |
| BR (1) | BR112018000468A2 (https=) |
| CA (1) | CA2991765C (https=) |
| CY (1) | CY1123007T1 (https=) |
| DK (1) | DK3319963T3 (https=) |
| EA (1) | EA033197B1 (https=) |
| ES (1) | ES2781867T3 (https=) |
| HR (1) | HRP20200410T1 (https=) |
| HU (1) | HUE047460T2 (https=) |
| IL (1) | IL256758A (https=) |
| LT (1) | LT3319963T (https=) |
| MA (1) | MA42397B1 (https=) |
| MD (1) | MD3319963T2 (https=) |
| MX (1) | MX2018000352A (https=) |
| PL (1) | PL3319963T3 (https=) |
| PT (1) | PT3319963T (https=) |
| SI (1) | SI3319963T1 (https=) |
| SM (1) | SMT202000134T1 (https=) |
| WO (1) | WO2017007938A1 (https=) |
| ZA (1) | ZA201800827B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| WO2016025917A1 (en) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| AU2016291158B2 (en) | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| US10071988B2 (en) | 2016-02-10 | 2018-09-11 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| WO2019193516A2 (en) * | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
| TW202112774A (zh) | 2019-06-14 | 2021-04-01 | 比利時商健生藥品公司 | 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途 |
| AU2020293642A1 (en) * | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| CA3143103A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as glun2b receptor modulators |
| MX2021015511A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de pirazina y sus usos como moduladores del receptor glun2b. |
| JP7667097B2 (ja) * | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| BR112021025141A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b |
| CN114008052A (zh) * | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
| CN114621125B (zh) * | 2020-12-14 | 2024-07-09 | 中国科学技术大学 | Nlrp3炎症小体抑制剂及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60316542T2 (de) * | 2002-03-28 | 2008-07-03 | Eisai R&D Management Co., Ltd. | 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen |
| RU2006127575A (ru) | 2004-02-18 | 2008-03-27 | Астразенека Аб (Se) | Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
| US20060183758A1 (en) * | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
| WO2007115231A2 (en) * | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| EP2167464B1 (en) | 2007-05-25 | 2014-12-03 | AbbVie Deutschland GmbH & Co KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor) |
| WO2009005821A1 (en) | 2007-07-03 | 2009-01-08 | Edward Scott Carlson | Support apparatus for climbing plants |
| JPWO2009028543A1 (ja) | 2007-08-30 | 2010-12-02 | 武田薬品工業株式会社 | 置換ピラゾール誘導体 |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
| MX2010009649A (es) | 2008-03-27 | 2010-12-17 | Evotecv Neurosciences Gmbh | Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda. |
| BRPI0917540A2 (pt) | 2008-08-05 | 2015-11-17 | Daiichi Sankyo Co Ltd | composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável |
| WO2010043396A1 (en) * | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| WO2010068483A2 (en) | 2008-11-25 | 2010-06-17 | University Of Rochester | Mlk inhibitors and methods of use |
| TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| EP2579717A4 (en) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| WO2014124651A1 (en) * | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| EP2970200A1 (en) * | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| DK2970265T3 (en) * | 2013-03-15 | 2018-10-01 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| CN103626767A (zh) * | 2013-12-04 | 2014-03-12 | 上海药明康德新药开发有限公司 | 区域选择性的氮杂吲哚及其合成方法 |
| WO2016025917A1 (en) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| AU2016291158B2 (en) * | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| US10071988B2 (en) | 2016-02-10 | 2018-09-11 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
-
2016
- 2016-07-07 AU AU2016291158A patent/AU2016291158B2/en not_active Ceased
- 2016-07-07 LT LTEP16741469.7T patent/LT3319963T/lt unknown
- 2016-07-07 BR BR112018000468-5A patent/BR112018000468A2/pt not_active Application Discontinuation
- 2016-07-07 MA MA42397A patent/MA42397B1/fr unknown
- 2016-07-07 MX MX2018000352A patent/MX2018000352A/es unknown
- 2016-07-07 EP EP16741469.7A patent/EP3319963B1/en active Active
- 2016-07-07 HR HRP20200410TT patent/HRP20200410T1/hr unknown
- 2016-07-07 SI SI201630594T patent/SI3319963T1/sl unknown
- 2016-07-07 JP JP2018500737A patent/JP6964576B2/ja active Active
- 2016-07-07 WO PCT/US2016/041339 patent/WO2017007938A1/en not_active Ceased
- 2016-07-07 MD MDE20180505T patent/MD3319963T2/ro not_active IP Right Cessation
- 2016-07-07 EA EA201890245A patent/EA033197B1/ru not_active IP Right Cessation
- 2016-07-07 PL PL16741469T patent/PL3319963T3/pl unknown
- 2016-07-07 KR KR1020187003560A patent/KR20180026760A/ko not_active Withdrawn
- 2016-07-07 PT PT167414697T patent/PT3319963T/pt unknown
- 2016-07-07 HU HUE16741469A patent/HUE047460T2/hu unknown
- 2016-07-07 ES ES16741469T patent/ES2781867T3/es active Active
- 2016-07-07 SM SM20200134T patent/SMT202000134T1/it unknown
- 2016-07-07 DK DK16741469.7T patent/DK3319963T3/da active
- 2016-07-07 CN CN201680052507.9A patent/CN108026094B/zh active Active
- 2016-07-07 CA CA2991765A patent/CA2991765C/en active Active
- 2016-07-08 US US15/205,632 patent/US9963447B2/en active Active
-
2018
- 2018-01-07 IL IL256758A patent/IL256758A/en unknown
- 2018-02-08 ZA ZA2018/00827A patent/ZA201800827B/en unknown
- 2018-03-20 US US15/926,440 patent/US10377753B2/en active Active
-
2020
- 2020-03-24 CY CY20201100280T patent/CY1123007T1/el unknown
-
2021
- 2021-08-27 JP JP2021138906A patent/JP7369743B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123007T1 (el) | Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b | |
| CY1124998T1 (el) | Ετεροκυκλικες ενωσεις και χρήσεις αυτων | |
| CY1124918T1 (el) | Ρυθμιστες ccr2 | |
| CY1121359T1 (el) | Ενωσεις ετεροαρυλιου για αναστολη κινασης | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1123920T1 (el) | Αντιγριπικο πολυκυκλικο παραγωγο πυριδονης και προφαρμακο αυτου | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1121542T1 (el) | Μορια αντισωματων σε pd-1 και χρηση αυτων | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| BR112018016329A2 (pt) | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b | |
| SI3394094T1 (sl) | T celični receptorji, specifični za NY-ESO-1 tumorski kompleks antigen-HLA-A*02 | |
| MX382339B (es) | Inhibidores g12c de kras. | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| CL2017001459A1 (es) | Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología | |
| EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
| LT3472153T (lt) | Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
| BR112018011709A2 (pt) | inibidores bicíclicos de pad4 | |
| BR112016013485A2 (pt) | Método para preparar um produto lácteo tendo teor estável de galacto-oligossacarídeo(s) | |
| CY1120535T1 (el) | Δοτες νιτροξυλιου με βελτιωμενο θεραπευτικο δεικτη |